SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner

Molecular and Cellular Biology

Volumn 31, Issue 6, 2011, Pages 1121-1133

  Rada, Patricia ^a,b   Rojo, Ana I ^a,b   Chowdhry, Sudhir ^c   McMahon, Michael ^c   Hayes, John D ^c   Cuadrado, Antonio ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; UBIQUITINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE; CYTOSKELETAL PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SERINE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 79952256187     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01204-10     Document Type: Article

References (55)

1. Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler. 1997. Betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797-3804.
2. Apopa, P. L., X. He, and Q. Ma. 2008. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J. Biochem. Mol. Toxicol. 22:63-76.
3. Calkins, M. J., et al. 2009. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 11:497-508.
4. Cuadrado, A., P. Moreno-Murciano, and J. Pedraza-Chaverri. 2009. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin. Ther. Targets 13:319-329.
5. Cullinan, S. B., J. D. Gordan, J. Jin, J. W. Harper, and J. A. Diehl. 2004. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24:8477-8486.
6. Cullinan, S. B., et al. 2003. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 23:7198-7209.
7. Ding, Q., et al. 2007. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27:4006-4017.
8. Dinkova-Kostova, A. T., et al. 2002. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 99:11908-11913.
9. Feldman, R. M., C. C. Correll, K. B. Kaplan, and R. J. Deshaies. 1997. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91:221-230.
10. Furukawa, M., and Y. Xiong. 2005. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 25:162-171.
11. Hayakawa, M., H. Kitagawa, K. Miyazawa, M. Kitagawa, and K. Kikugawa. 2005. The FWD1/beta-TrCP-mediated degradation pathway establishes a 'turning off switch' of a Cdc42 guanine nucleotide exchange factor, FGD1. Genes Cells 10:241-251.
12. Hayakawa, M., et al. 2008. Novel insights into FGD3, a putative GEF for Cdc42, that undergoes SCF(FWD1/beta-TrCP)-mediated proteasomal degradation analogous to that of its homologue FGD1 but regulates cell morphology and motility differently from FGD1. Genes Cells 13:329-342. (Pubitemid 351437020)
13. Hayes, J. D., and M. McMahon. 2009. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34:176-188.
14. Homma, S., et al. 2009. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 15:3423-3432.
15. Huang, H. C., T. Nguyen, and C. B. Pickett. 2000. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc. Natl. Acad. Sci. U. S. A. 97:12475-12480.
16. Innamorato, N. G., I. Lastres-Becker, and A. Cuadrado. 2009. Role of microglial redox balance in modulation of neuroinflammation. Current Opin. Neurol. 22:308-314.
17. Innamorato, N. G., et al. 2008. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 181:680-689.
18. Jain, A. K., and A. K. Jaiswal. 2006. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J. Biol. Chem. 281:12132-12142.
19. Kang, T., et al. 2008. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13:36-47. (Pubitemid 350309739)
20. Kobayashi, A., et al. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24:7130-7139.
21. Kobayashi, M., and M. Yamamoto. 2006. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 46:113-140.
22. Latres, E., D. S. Chiaur, and M. Pagano. 1999. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18:849-854. (Pubitemid 29086261)
23. Li, X., J. Liu, and T. Gao. 2009. Beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol. Cell. Biol. 29:6192-6205.
24. Limon-Mortes, M. C., et al. 2008. UV-induced degradation of securin is mediated by SKP1-CUL1-beta TrCP E3 ubiquitin ligase. J. Cell Sci. 121: 1825-1831. (Pubitemid 351943375)
25. Maher, J., and M. Yamamoto. 2010. The rise of antioxidant signaling - the evolution and hormetic actions of Nrf2. Toxicol. Appl. Pharmacol. 244:4-15.
26. Martin, D., et al. 2004. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J. Biol. Chem. 279:8919-8929.
27. Martin, D., M. Salinas, N. Fujita, T. Tsuruo, and A. Cuadrado. 2002. Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J. Biol. Chem. 277:42943-42952.
28. McMahon, M., N. Thomas, K. Itoh, M. Yamamoto, and J. D. Hayes. 2006. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281:24756-24768.
29. McMahon, M., N. Thomas, K. Itoh, M. Yamamoto, and J. D. Hayes. 2004. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem. 279:31556-31567.
30. Meijer, L., M. Flajolet, and P. Greengard. 2004. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25:471-480.
31. Meyer, L., et al. 2007. Beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 109:5215-5222. (Pubitemid 46890539)
32. Nioi, P., and T. Nguyen. 2007. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 362:816-821.
33. Pan, Y., C. B. Bai, A. L. Joyner, and B. Wang. 2006. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol. Cell. Biol. 26:3365-3377.
34. Papkoff, J., and M. Aikawa. 1998. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 247:851-858.
35. Petroski, M. D., and R. J. Deshaies. 2005. In vitro reconstitution of SCF substrate ubiquitination with purified proteins. Methods Enzymol. 398:143-158.
36. Pi, J., et al. 2007. Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic. Biol. Med. 42:1797-1806.
37. Rojo, A. I., et al. 2008. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol. Cell Neurosci. 39:125-132.
38. Rojo, A. I., M. R. Sagarra, and A. Cuadrado. 2008. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 105:192-202. (Pubitemid 351441636)
39. Salazar, M., A. I. Rojo, D. Velasco, R. M. de Sagarra, and A. Cuadrado. 2006. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 281:14841-14851.
40. Salinas, M., R. Lopez-Valdaliso, D. Martin, A. Alvarez, and A. Cuadrado. 2000. Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol. Cell Neurosci. 15:156-169.
41. Shibata, T., et al. 2008. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105:13568-13573.
42. Skowyra, D., K. L. Craig, M. Tyers, S. J. Elledge, and J. W. Harper. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209-219.
43. Suh, J. H., et al. 2004. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 101:3381-3386.
44. Sun, Z., Z. Huang, and D. D. Zhang. 2009. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PloS One 4:e6588.
45. Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-798. (Pubitemid 24294454)
46. Varghese, B., et al. 2008. Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol. Cell. Biol. 28:5275-5287.
47. Wakabayashi, N., et al. 2004. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad. Sci. U. S. A. 101:2040-2045.
48. Wang, B., and Y. Li. 2006. Evidence for the direct involvement of βTrCP in Gli3 protein processing. Proc. Natl. Acad. Sci. U. S. A. 103:33-38.
49. Yu, X., and T. Kensler. 2005. Nrf2 as a target for cancer chemoprevention. Mutation Res. 591:93-102. (Pubitemid 41654841)
50. Zhang, D. D., and M. Hannink. 2003. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23: 8137-8151.
51. Zhang, D. D., S. C. Lo, J. V. Cross, D. J. Templeton, and M. Hannink. 2004. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24:10941-10953.
52. Zhao, B., L. Li, K. Tumaneng, C. Y. Wang, and K. L. Guan. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24:72-85.
53. Zhao, F., et al. 2009. Nrf2 promotes neuronal cell differentiation. Free Radic. Biol. Med. 47:867-879.
54. Zhou, B. P., et al. 2004. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell biol. 6:931-940.
55. Zhu, Z., and M. Kirschner. 2002. Regulated proteolysis of Xom mediates dorsoventral pattern formation during early Xenopus development. Dev. Cell 3:557-568. (Pubitemid 35252264)